Sugi Predict

Sugi Predict / Compounds / SCHEMBL69470

SCHEMBL69470

SCHEMBL69470

CC(C)(C)c1ccccc1NC1CCN(C(=O)CNC(=O)c2cc(-c3ccccc3)[nH]n2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCD O00767 4/20 0.44
▸ P2RY12 Q9H244 8/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ KDM5B Q9UGL1 2/20 0.37
▸ RBP4 P02753 1/20 0.36
▸ KDM5A P29375 1/20 0.35
▸ DCLK1 O15075 1/20 0.35
▸ PDPK1 O15530 1/20 0.35
▸ PRKD3 O94806 1/20 0.35
▸ MAP4K4 O95819 1/20 0.35
▸ CHEK2 O96017 1/20 0.35
▸ PIM1 P11309 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ AXL P30530 1/20 0.35
▸ FLT4 P35916 1/20 0.35
▸ FLT3 P36888 1/20 0.35
▸ MAPK9 P45984 1/20 0.35
▸ CSNK1D P48730 1/20 0.35
▸ IRAK1 P51617 1/20 0.35
▸ RPS6KA3 P51812 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29384715 0.89 P2RY12 (0.44) SCDP2RY12SMN1; SMN2KDM5BMAPK1
SCHEMBL69043 0.89 P2RY12 (0.44) SCDP2RY12SMN1; SMN2KDM5BMAPK1
SCHEMBL70773 0.87 P2RY12 (0.41) SCDP2RY12SMN1; SMN2KDM5BKDM5A
SCHEMBL70832 0.87 SCD (0.43) SCDP2RY12SMN1; SMN2KDM5AMAPK9
SCHEMBL29384862 0.86 P2RY12 (0.44) SCDP2RY12SMN1; SMN2KDM5A
SCHEMBL69114 0.86 P2RY12 (0.44) SCDP2RY12SMN1; SMN2KDM5A
SCHEMBL71092 0.85 SCD (0.44) SCDP2RY12RBP4
SCHEMBL29384738 0.85 SCD (0.44) SCDP2RY12RBP4
SCHEMBL69533 0.84 P2RY12 (0.43) P2RY12SMN1; SMN2KDM5BFLT3
SCHEMBL29381941 0.84 P2RY12 (0.43) P2RY12SMN1; SMN2KDM5BFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2268143-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE Forest Laboratories Holdings Limited (BM) 2011-01-05 — — EP claimed
US-8129376-B2 Piperidine derivatives as inhibitors of stearoyl-CoA desaturase AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-03-06 — — US disclosed
EP-2268143-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE Forest Laboratories Holdings Limited (BM) 2011-01-05 — — EP disclosed
WO-2009117676-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 — — WO disclosed
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE SCD, SCD5, FADS2 SCD 1/4885P2RY12 3918/4885SMN1; SMN2 3937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.